Dara Biosciences, a development-stage pharmaceutical company, has announced that the FDA has cleared the company’s investigational new drug application for DB959, allowing Dara to commence Phase I studies
Cell Genesys, a biotechnology company, has reported a net loss of $13.3m, or $0.15 per diluted share, for the fourth quarter of 2008, compared to a net loss
EnteroMedics, a medical device company, has received the CE Mark approval for its Vbloc therapy delivered via the Maestro system for the treatment of obesity. The Maestro system
The company reported revenues of $82.85 million for the year ended December 31, 2008, compared to $44.34 million for the year ended December 31, 2007. The increase in
Eurand, a specialty pharmaceutical company, has received the FDA orphan drug designation for EUR-1073 in pediatric patients. EUR-1073 is a proprietary development product for the treatment of ulcerative
For the 12 months ended December 31, 2008, the company reported a net loss of $8 million, or $0.43 per share, compared to a net loss of $24.6
According to the company, the HemAway Seat is a painless, non-invasive, discreet, and easy-to-use hemorrhoid treatment device that alleviates the discomfort and agony of prolapsed internal hemorrhoids within
In its filing with the bankruptcy court, North American Scientific (NASM) cited that its bank, pursuant to its rights under certain lending agreements, had reduced the company’s borrowing
Dr Batchelor will lead the company’s pursuit of discovering and developing small molecules and biologics to guide cell fate for therapeutic purposes. Dr Batchelor brings more than 28
Advaxis, a development-stage biotechnology company, has submitted to the FDA its lead drug candidate, ADXS11-001, for orphan drug designation to treat invasive carcinoma of the cervix. The orphan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.